Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive
offsodes.
Berzewski H, Van Moffaert M, Gagiano CA
German Reboxetine Study Group,
Freie Universitat Berlin,
Germany.
Eur Neuropsychopharmacol 1997 Apr; 7 Suppl 1:S37-47; discussion S71-3
ABSTRACT
A 6-week, randomised, double-blind, multicentre study in 256 patients with a DSM-III-R diagnosis of major depression was carried out to compare the selective noradrenaline reuptake inhibitor (NARI), reboxetine, with the reference standard tricyclic antidepressant, imipramine. The efficacy of reboxetine, as measured by the extent of improvement of Hamilton Depression Rating Scale. Montgomery and Asberg Depression Rating Scale and the Clinical Global Impression Scale, was similar to that of imipramine. The improvement was observed in the overall population and in severely depressed and melancholic patients. Reboxetine tolerability compared favourably with that of imipramine. Frequency of discontinuation due to adverse events was lower in the reboxetine-treated group (10.0%) than in the imipramine-treated group (14.3%), and the cumulative risk of development (Kaplan-Meier analysis) of dry mouth, hypotension and/or related symptoms and tremor was significantly higher on imipramine than on
reboxetine.
Reboxetine research
/ abstracts
1. Reboxetine
role in antidepressant therapy
2. Reboxetine
efficacy and tolerability
3. Reboxetine
clinical
pharmacologic profile
4. Inhibiting
the reuptake of noradrenaline and serotonin
5. Reboxetine
and depression in the elderly
6. Reboxetine
with severe major depressive disorder
7. Reboxetine
clinical
efficacy in major depression
8. Reboxetine
tolerability
and safety for major depression
9. Reboxetine
comparison with fluoxetine
10 Reboxetine
versus fluoxetine, impact on social functioning
11. Reboxetine versus
fluoxetine, differential effects
12. Reboxetine
prevents relapse in major depression
13 Reboxetine
efficacy compared with imipramine
14. Noradrenaline
reuptake inhibition
15. Antidepressants
noradrenergic
versus serotonergic
16. Reboxetine
in the treatment of bulimia
17.
Reboxetine
hemodynamic effects in healthy males
18. Reboxetine
effects of antidepressant therapy
19. Reboxetine
place in antidepressant
therapy
20. Reboxetine
stimulant effects in patients with narcolepsy
21. Reboxetine
selective noradrenaline reuptake inhibitor (NARI)
